Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives $129.83 Consensus Price Target from Brokerages

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) have been assigned a consensus rating of “Moderate Buy” from the fifteen ratings firms that are currently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $129.8333.

Several equities analysts have recently weighed in on DNTH shares. Wedbush raised their price target on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a report on Wednesday, August 5th. Weiss Ratings restated a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Friday, July 17th. HC Wainwright lifted their target price on shares of Dianthus Therapeutics from $130.00 to $158.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Wolfe Research reiterated an “outperform” rating on shares of Dianthus Therapeutics in a research note on Wednesday, June 10th. Finally, Truist Financial increased their price target on shares of Dianthus Therapeutics from $110.00 to $128.00 and gave the company a “buy” rating in a report on Thursday, August 6th.

Dianthus Therapeutics Stock Down 4.3%

Shares of DNTH opened at $96.81 on Friday. The stock has a market cap of $5.29 billion, a P/E ratio of -23.33 and a beta of 1.24. The business’s 50 day moving average price is $107.03 and its 200-day moving average price is $92.84. Dianthus Therapeutics has a 52 week low of $32.22 and a 52 week high of $117.88.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.05). Dianthus Therapeutics had a negative net margin of 10,096.95% and a negative return on equity of 22.53%. The company had revenue of $0.76 million for the quarter, compared to the consensus estimate of $0.30 million. On average, equities analysts anticipate that Dianthus Therapeutics will post -3.81 EPS for the current year.

Insider Buying and Selling

In other Dianthus Therapeutics news, SVP Adam M. Veness sold 16,167 shares of Dianthus Therapeutics stock in a transaction on Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the completion of the sale, the senior vice president owned 3,833 shares of the company’s stock, valued at approximately $423,086.54. This trade represents a 80.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Marino Garcia sold 166,000 shares of Dianthus Therapeutics stock in a transaction on Friday, August 7th. The stock was sold at an average price of $108.11, for a total value of $17,946,260.00. Following the completion of the sale, the chief executive officer directly owned 65,292 shares of the company’s stock, valued at approximately $7,058,718.12. The trade was a 71.77% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 273,678 shares of company stock worth $29,276,000 over the last 90 days. 3.02% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

Several institutional investors have recently modified their holdings of the business. Arizona State Retirement System increased its holdings in Dianthus Therapeutics by 5.7% in the 2nd quarter. Arizona State Retirement System now owns 10,141 shares of the company’s stock worth $989,000 after buying an additional 546 shares in the last quarter. Nykredit A S purchased a new position in Dianthus Therapeutics in the 2nd quarter worth about $147,000. Amundi purchased a new stake in shares of Dianthus Therapeutics during the 2nd quarter valued at about $287,000. VIRGINIA RETIREMENT SYSTEMS ET Al bought a new stake in shares of Dianthus Therapeutics in the second quarter worth approximately $1,033,000. Finally, Alyeska Investment Group L.P. grew its stake in shares of Dianthus Therapeutics by 188.2% in the second quarter. Alyeska Investment Group L.P. now owns 150,592 shares of the company’s stock worth $14,680,000 after acquiring an additional 98,345 shares during the period. 47.53% of the stock is owned by hedge funds and other institutional investors.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody-based medicines for complement-mediated diseases. The complement system is part of the immune system, and abnormal activation can contribute to autoimmune and inflammatory disorders. Dianthus is developing therapies designed to selectively inhibit complement activity while offering potentially durable treatment effects.

The company’s lead product candidate, DNTH103, is an investigational monoclonal antibody designed to inhibit C1s, a protein involved in the classical complement pathway.